Tisento Therapeutics

Tisento Therapeutics is a pioneering biotechnology research company dedicated to developing innovative solutions for debilitating diseases. With a commitment to understanding and addressing unmet medical needs, Tisento Therapeutics focuses on delivering medicines that truly make a difference in patients' lives. The company places significant emphasis on listening to patients, healthcare providers, and regulatory agencies, ensuring that their research and development efforts are aligned with the most pressing needs in the medical community.

At the forefront of Tisento Therapeutics' pipeline is zagociguat (formerly CY6463), a Phase 2, first-in-class, brain-penetrant sGC stimulator. This promising candidate is currently advancing in clinical trials for MELAS and other genetic mitochondrial diseases. Zagociguat is uniquely positioned to treat mitochondrial diseases that manifest with both central nervous system (CNS) and peripheral symptoms, such as cognitive impairment, fatigue, and muscle weakness. Tisento Therapeutics is committed to advancing this and other innovative therapies to improve the quality of life for individuals affected by these conditions.

Tisento Therapeutics remains steadfast in its mission to drive medical innovation and provide effective treatment options for those who need them most. The company's commitment to listening, understanding, and innovating sets it apart as a leader in the biotechnology sector. We invite the manager of Tisento Therapeutics to create a customized and exclusive company showcase and product listing on our platform to further highlight their groundbreaking work.